[1] 代志新, 杜鹏, 董隽含. 中国老年抚养比再估计与人口老龄化趋势再审视[J]. 人口研究, 2023, 47(3): 94-107. [2] 沈珊珊, 曾幸坤, 张靖梅, 等. 老年住院患者营养不良和肌少症与失能的相关性研究[J]. 中华老年医学杂志, 2022, 41(4): 383-387. [3] ARNAU A, ESPAULELLA J, MÉNDEZ T, et al. Lower limb function and 10-year survival in population aged 75 years and older[J]. Fam Pract, 2016, 33(1): 10-16. [4] GE J, ZENG J, MA H, et al. A new index based on serum creatinine and cystatin C can predict the risks of sarcopenia, falls and fractures in old patients with low bone mineral density[J]. Nutrients, 2022, 14(23): 5020. [5] 赖飘, 张俐, 吴永华, 等. 血清Klotho蛋白水平与老年衰弱的相关性研究[J]. 中华老年医学杂志, 2024, 43(3): 372-377. [6] KASHANI K B, FRAZEE E N, KUKRÁLOVÁ L, et al. Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index[J]. Crit Care Med, 2017, 45(1): e23-e29. [7] HIRAI K, TANAKA A, HOMMA T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J]. Clin Nutr, 2021, 40(3): 1274-1280. [8] KASHANI K, SARVOTTAM K, PEREIRA N L, et al. The sarcopenia index: a novel measure of muscle mass in lung transplant candidates[J]. Clin Transplant, 2018, 32(3): e13182. [9] 高卉, 季雨, 赵娟, 等. 肌少症指数对老年2型糖尿病患者早期糖尿病肾病的预测价值研究[J]. 检验医学与临床, 2023, 20(11): 1556-1559. [10] JUNG C Y, KIM H W, HAN S H, et al. Creatinine-cystatin C ratio and mortality in cancer patients: a retrospective cohort study[J]. J Cachexia Sarcopenia Muscle, 2022, 13(4): 2064-2072. [11] SHI S, JIANG Y, CHEN W, et al. Diagnostic and prognostic value of the Creatinine/Cystatin C ratio for low muscle mass evaluation among US adults[J]. Front Nutr, 2022, 9: 897774. [12] WANG D X M, YAO J, ZIREK Y, et al. Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2020, 11(1): 3-25. [13] TINTIGNAC L A, BRENNER H R, RÜEGG M A. Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting[J]. Physiol Rev, 2015, 95(3): 809-852. [14] EVANS W J, PAOLISSO G, ABBATECOLA A M, et al. Frailty and muscle metabolism dysregulation in the elderly[J]. Biogerontology, 2010, 11(5): 527-536. [15] INZITARI M, METTI A, ROSANO C, et al. Qualitative neurological gait abnormalities, cardiovascular risk factors and functional status in older community-dwellers without neurological diseases: the Healthy Brain Project[J]. Exp Gerontol, 2019, 124: 110652. [16] LIVSHITS G, KALINKOVICH A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis[J]. Ageing Res Rev, 2019, 56: 100980. [17] 夏运, 张光第. 老年女性2型糖尿病病人血清肌酐/胱抑素C比值与胰岛B细胞功能的相关性研究[J]. 实用老年医学, 2023, 37(6): 607-611. [18] PICCA A, CALVANI R. Molecular mechanism and pathogenesis of sarcopenia: an overview[J]. Int J Mol Sci, 2021, 22(6): 3032. |